# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k112538   
B. Purpose for Submission: Additional or Expanded Indications: adding lithium heparin plasma as a new claim   
C. Measurand: Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, and Triglycerides   
D. Type of Test: Quantitative, colorimetric   
E. Applicant: Alfa Wassermann Diagnostic Technologies, LLC.

# F. Proprietary and Established Names:

ACE Cholesterol Reagent ACE HDL-C Reagent ACE LDL-C Reagent ACE Triglycerides Reagent

# G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td></tr><tr><td rowspan=1 colspan=1>ACE Cholesterol Reagent</td><td rowspan=1 colspan=1>21 C.F.R. § 862.1175</td><td rowspan=1 colspan=1>CHH</td><td rowspan=1 colspan=1>I, meets limitations per21 CFR 862.9(c)(4)</td></tr><tr><td rowspan=1 colspan=1>ACE HDL-C Reagent</td><td rowspan=1 colspan=1>21 C.F.R. § 862.1475</td><td rowspan=1 colspan=1>LBS</td><td rowspan=1 colspan=1>I, meets limitations per21 CFR 862.9(c)(4)</td></tr><tr><td rowspan=1 colspan=1>ACE LDL-C Reagent</td><td rowspan=1 colspan=1>21 C.F.R. § 862.1475</td><td rowspan=1 colspan=1>MRR</td><td rowspan=1 colspan=1>I, meets limitations per21 CFR 862.9(c)(4)</td></tr></table>

Page 2 of 28   

<table><tr><td>ACE Triglycerides Reagent</td><td>21 C.F.R. § 862.1705</td><td>CDT</td><td>I, meets limitations per 21 CFR 862.9(c)(4)</td></tr></table>

Panel: Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indications(s) for use:

ACE Cholesterol Reagent is intended for the quantitative determination of cholesterol in serum and lithium heparin plasma using the ACE and ACE Alera Clinical Chemistry Systems. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders. For in vitro diagnostic use only.

ACE HDL-C Reagent is intended for the homogeneous, quantitative determination of HDL cholesterol (HDL-C) in serum and lithium heparin plasma using the ACE and ACE Alera Clinical Chemistry Systems. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. For in vitro diagnostic use only.

ACE LDL-C Reagent is intended for the quantitative determination of low density lipoprotein cholesterol (LDL-C) in serum and lithium heparin plasma using the ACE and ACE Alera Clinical Chemistry Systems. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. For in vitro diagnostic use only.

ACE Triglycerides Reagent is intended for the quantitative determination of triglycerides in serum and lithium heparin plasma using the ACE and ACE Alera Clinical Chemistry Systems. Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism or various endocrine disorders. For in vitro diagnostic use only.

3. Special conditions for use statement(s): For prescription use.

4. Special instrument requirements:

# ACE and ACE Alera Clinical Chemistry Systems

# I. Device Description:

# ACE Cholesterol Reagent

The ACE Cholesterol Reagent, used with the ACE and ACE Alera Clinical Chemistry System, is intended for quantitative in vitro diagnostic determination of cholesterol concentration in serum and lithium heparin plasma. It is based on a photometric test using a coupled enzymatic reaction (cholesterol esterase, cholesterol oxidase and peroxidase), which produces color via the Trinder reaction. It is composed of one reagent bottle, which is placed in the reagent compartment of the ACE or ACE Alera. It is intended for in vitro diagnostic use.

# ACE HDL-C Reagent

The ACE HDL-C Reagent, used with the ACE and ACE Alera Clinical Chemistry System, is intended for quantitative in vitro diagnostic determination of high density lipoprotein cholesterol concentration in serum and lithium heparin plasma. It is based on a photometric test measuring the amount of HDL present utilizing two reagents, the second of which contains a unique detergent. This detergent solubilizes only the HDL lipoprotein particles, thus releasing HDL cholesterol to react with the cholesterol esterase and cholesterol oxidase, in the presence of a chromogen to produce color in the reaction cuvette. The detergent also inhibits the reaction of the cholesterol enzymes with LDL and VLDL lipoproteins and chylomicrons by adsorbing to their surfaces. It is composed of two reagent bottles, which are placed in the reagent compartment of the ACE or ACE Alera. It is intended for in vitro diagnostic use.

# ACE LDL-C Reagent

The ACE LDL-C Reagent, used with the ACE and ACE Alera Clinical Chemistry System, is intended for quantitative in vitro diagnostic determination of low density lipoprotein cholesterol concentration in serum and lithium heparin plasma. It is based on a photometric test measuring the amount of LDL present after other non-LDL cholesterol is solubilized by a detergent and then consumed by cholesterol esterase and cholesterol oxidase in a noncolor forming reaction. LDL is then solubilized by a second detergent in the presence of a chromogenic peroxidase substrate to form a purple-red color. It is composed of two reagent bottles, which are placed in the reagent compartment of the ACE or ACE Alera. It is intended for in vitro diagnostic use.

# ACE Triglycerides Reagent

The ACE Triglycerides Reagent, used with the ACE and ACE Alera Clinical Chemistry System, is intended for quantitative in vitro diagnostic determination of triglycerides concentration in serum and lithium heparin plasma. It is based on a photometric test using a coupled enzymatic reaction (lipase, glycerol kinase, glycerol phosphate oxidase and peroxidase), which produces color via the Trinder reaction. It is composed of one reagent bottle, which is placed in the reagent compartment of the ACE or ACE Alera. It is intended for in vitro diagnostic use.

# J. Substantial Equivalence Information:

1. Predicate device name(s):

ACE Cholesterol Reagent ACE HDL-C Reagent ACE LDL-C Reagent ACE Triglycerides Reagent

2. Predicate 510(k) number(s): ACE Cholesterol Reagent: k931786 ACE HDL-C Reagent: k931876 ACE LDL-C Reagent: k991733 ACE Triglycerides Reagent: k931786

3. Comparison with predicate:

# Device Comparison Table: ACE Cholesterol Reagent

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE Cholesterol Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/Clinical ChemistrySystem,ACE Cholesterol Reagent</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor Use</td><td rowspan=1 colspan=1>ACE Cholesterol Reagent is intended forthe quantitative determination ofcholesterol using the ACE and ACE AleraClinical Chemistry Systems. For in vitrodiagnostic use only.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum or lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatforms</td><td rowspan=1 colspan=1>ACE and ACE Alera Clinical ChemistrySystems</td><td rowspan=1 colspan=1>ACE, ACE Alera® and NExCTTMClinical Chemistry Systems</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Calibrated by referencing the change inabsorbance of the unknown samples tothe change in absorbance of thecalibrator; the use of GEMCALReference Serum is recommended.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-BoardStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr></table>

Page 5 of 28   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE Cholesterol Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/Clinical ChemistrySystem,ACE Cholesterol Reagent</td></tr><tr><td rowspan=1 colspan=1>MethodTraceability</td><td rowspan=1 colspan=1>Abell, L.L., Levy, B.B., Brodie, B.B. andKendall, F.E., J. Biol. Chem. 195, 357(1952); Allain, C.C., Poon, L.S., Chan,C.S.G, Richmond, W. and Fu, P.C., Clin.Chem. 20, 470 (1974).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReactiveIngredients</td><td rowspan=1 colspan=1>4-Aminoantipyrenep-Hydroxybenzoic acidCholesterol oxidase (Nocardia)Cholesterol esterase (porcine pancreasand Pseudomonas)Peroxidase (Horseradish)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalysisTemperature</td><td rowspan=1 colspan=1>37°</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>3μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Precision(mg/dL)</td><td rowspan=1 colspan=1>Within run:Sample A: Mean 139, SD 3.0, CV 2.2%Sample B: Mean 212, SD 2.4, CV 1.1%Sample C: Mean 290, SD 5.7, CV 2.0%Total:Sample A: Mean 139, SD 3.2, CV 2.3%Sample B: Mean 212, SD 3.3, CV 1.6%Sample C: Mean 290, SD 6.0, CV 2.1%</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MatrixComparison</td><td rowspan=1 colspan=1>x = serum, y = lithium heparin plasmaACE:Regression Equation: y = 0.985x - 1.7Correlation Coefficient: 0.9947Sample Range: 40-568ACE Alera:Regression Equation: y = 0.994x - 2.5Correlation Coefficient: 0.9934Sample Range: 42-577</td><td rowspan=1 colspan=1>Serum only</td></tr><tr><td rowspan=1 colspan=1>DetectionWavelength</td><td rowspan=1 colspan=1>505/647 nm</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Device Comparison Table: ACE HDL-C Reagent

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE HDL-C Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/Clinical ChemistrySystem,ACE HDL-C Reagent</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indications for Use</td><td rowspan=1 colspan=1>ACE HDL-C Reagent is intended for thehomogeneous, quantitative determination ofHDL cholesterol (HDL-C) using the ACEand ACE Alera Clinical ChemistrySystems. For in vitro diagnostic use only.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum or lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatforms</td><td rowspan=1 colspan=1>ACE and ACE Alera Clinical ChemistrySystems</td><td rowspan=1 colspan=1>ACE and ACE Alera® ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Calibrated by referencing the change inabsorbance of the unknown samples to thechange in absorbance of the calibrator; theuse of GEMCAL Reference Serum isrecommended.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-BoardStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MethodTraceability</td><td rowspan=1 colspan=1>Gotto, A.M., Lipoprotein metabolism andthe etiology of hyperlipidemia, HospitalPractice, 23:Suppl. 1, 4 (1988).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReactiveIngredients</td><td rowspan=1 colspan=1>BufferCholesterol oxidase (E. coli)Peroxidase (Horseradish)N, N-bis(4-sulphobutyl)-m-toluidine-disodium saltAcceleratorAscorbic oxidase (Curcurbita sp.)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalysisTemperature</td><td rowspan=1 colspan=1>37°C</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=1>3 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Precision(mg/dL)</td><td rowspan=1 colspan=1>Within run:Sample A: Mean 32, SD 0.7, CV 2.0%Sample B: Mean 61, SD 1.2, CV 2.0%</td><td rowspan=1 colspan=1>Same</td></tr></table>

Page 7 of 28   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE HDL-C Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/Clinical ChemistrySystem,ACE HDL-C Reagent</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Sample C: Mean 85, SD 1.5, CV 1.8%Total:Sample A: Mean 32, SD 1.3, CV 4.2%Sample B: Mean 61, SD 2.6, CV 4.3%Sample C: Mean 85, SD 3.3, CV 3.9%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>ComparativeAnalysisRegressionEvaluation</td><td rowspan=1 colspan=1>Regression Equation: y = 0.954x + 1.9Correlation Coefficient: 0.988Sample Range: 15-120 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ExpectedValues</td><td rowspan=1 colspan=1>40 to 60 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MatrixComparison</td><td rowspan=1 colspan=1>x = serum, y = lithium heparin plasmaACE:Regression Equation: y = 1.015x - 0.6Correlation Coefficient: 0.9884Sample Range: 6-120ACE Alera:Regression Equation: y = 0.989x + 0.4Correlation Coefficient: 0.9874Sample Range: 7-123</td><td rowspan=1 colspan=1>Serum only</td></tr><tr><td rowspan=1 colspan=1>DetectionWavelength</td><td rowspan=1 colspan=1>592/692 nm</td><td rowspan=1 colspan=1>Same</td></tr></table>

Device Comparison Table: ACE LDL-C Reagent   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Company</td><td rowspan=1 colspan=1>Alfa Wassermann DiagnosticTechnologies, LLC</td><td rowspan=1 colspan=1>Alfa Wassermann DiagnosticTechnologies, LLC</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE LDL-C Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/ClinicalChemistry System,ACE LDL-C Reagent</td></tr><tr><td rowspan=1 colspan=1>Intended Use/Indicationsfor Use</td><td rowspan=1 colspan=1>ACE LDL-C Reagent is intended forthe quantitative determination of lowdensity lipoprotein cholesterol (LDL-C) using the ACE and ACE AleraClinical Chemistry Systems. For invitro diagnostic use only.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum or lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatforms</td><td rowspan=1 colspan=1>ACE and ACE Alera ClinicalChemistry Systems</td><td rowspan=1 colspan=1>ACE and the NExCT ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Calibrated by referencing the changein absorbance of the unknown samplesto the change in absorbance of thecalibrator; the use of LDL-CCalibrator is recommended.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationStability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-BoardStability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MethodTraceability</td><td rowspan=1 colspan=1>Gotto, A.M., Lipoprotein metabolismand the etiology of hyperlipidemia,Hospital Practice, 23: Suppl. 1, 4(1998); Crouse, J.R. et al. Studies oflow density lipoprotein molecularweight in human beings with coronaryartery disease J. Lipids Res., 26, 566(1985).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReactiveIngredients</td><td rowspan=1 colspan=1>Cholesterol esteraseCholesterol oxidasePeroxidase4-AminoantipyrineAscorbic acid oxidaseBufferN,N-bis (4-sulfobutyl)-m-toluidine,disodium salt</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalysisTemperature</td><td rowspan=1 colspan=1>37°</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Volume</td><td rowspan=1 colspan=1>3 μL</td><td rowspan=1 colspan=1>Same</td></tr></table>

Page 9 of 28   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Company</td><td rowspan=1 colspan=1>Alfa Wassermann DiagnosticTechnologies, LLC</td><td rowspan=1 colspan=1>Alfa Wassermann DiagnosticTechnologies, LLC</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE LDL-C Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/ClinicalChemistry System,ACE LDL-C Reagent</td></tr><tr><td rowspan=1 colspan=1>Reaction Volume(total)</td><td rowspan=1 colspan=1>418 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Precision(mg/dL)</td><td rowspan=1 colspan=1>Within-Run:Sample A: Mean 95, SD 2.1, CV 2.2%Sample B: Mean 146, SD 3.8, CV2.6%Sample C: Mean 196, SD 2.8, CV1.4%Total:Sample A: Mean 95, SD 2.5, CV 2.6%Sample B: Mean 146, SD 4.7, CV3.2%Sample C: Mean 196, SD 6.3, CV3.2%</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ComparativeAnalysisRegressionEvaluation</td><td rowspan=1 colspan=1>Regression Equation: y = 1.111x - 15.5Correlation Coefficient: 0.9747Sample Range: 41-226 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ExpectedValues</td><td rowspan=1 colspan=1>&lt;130 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MatrixComparison</td><td rowspan=1 colspan=1>x = serum, y = lithium heparin plasmaACE:Regression Equation: y = 1.008x - 2.6Correlation Coefficient: 0.9954Sample Range: 9-460ACE Alera:Regression Equation: y = 0.995x - 1.3Correlation Coefficient: 0.9954Sample Range: 9-464</td><td rowspan=1 colspan=1>Serum only</td></tr><tr><td rowspan=1 colspan=1>DetectionWavelength</td><td rowspan=1 colspan=1>544/692 nm</td><td rowspan=1 colspan=1>Same</td></tr></table>

Device Comparison Table: ACE Triglycerides Reagent   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE Triglycerides Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/ClinicalChemistry System,ACE Triglycerides Reagent</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indications for Use</td><td rowspan=1 colspan=1>ACE Triglycerides Reagent is intended forthe quantitative determination oftriglycerides using the ACE and ACE AleraClinical Chemistry Systems. For in vitrodiagnostic use only.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum or lithium heparin plasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatforms</td><td rowspan=1 colspan=1>ACE and ACE Alera Clinical ChemistrySystems</td><td rowspan=1 colspan=1>ACE, ACE Alera® and theNExCTTM Clinical ChemistrySystems</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Calibrated by referencing the change inabsorbance of the unknown samples to thechange in absorbance of the calibrator; theuse of GEMCAL Reference Serum isrecommended.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationStability:</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-BoardStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MethodTraceability</td><td rowspan=1 colspan=1>Frederickson, D.S., et al., New Engl. J.Med. 276, 32 (1976); Tietz, N.W. (Ed.),Textbook of Clinical Chemistry, W.B.Saunders Co., Philadelphia, PA (1986).</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReactiveIngredients</td><td rowspan=1 colspan=1>4-Aminoantipyrineadenosine 5&#x27;-triphosphatep-ChlorophenolGlycerol phosphate oxidase(Microorganism)Lipase (Pseudomonas)Peroxidase (Horseradish)Glycerol kinase (Cellulomonas)Buffer</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalysisTemperature</td><td rowspan=1 colspan=1>37°</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>SampleVolume</td><td rowspan=1 colspan=1>3 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ReactionVolume(total)</td><td rowspan=1 colspan=1>243 μL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>Within run:</td><td rowspan=1 colspan=1>Same</td></tr></table>

Page 11 of 28   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>510(k) #</td><td rowspan=1 colspan=1>K112538</td><td rowspan=1 colspan=1>K931786 (ACE)</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>ACE Triglycerides Reagent</td><td rowspan=1 colspan=1>ACE plus ISE/ClinicalChemistry System,ACE Triglycerides Reagent</td></tr><tr><td rowspan=1 colspan=1>(mg/dL)</td><td rowspan=1 colspan=1>Sample A: Mean 73 SD 1.3, CV 1.7%Sample B: Mean 142, SD 1.6, CV 1.2%Sample C: Mean 203, SD 2.4, CV 1.2%Total:Sample A: Mean 73, SD 1.4, CV 1.9%Sample B: Mean 142, SD 2.6, CV 1.8%Sample C: Mean 203, SD 4.0, CV 2.0%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>ComparativeAnalysisRegressionEvaluation</td><td rowspan=1 colspan=1>Regression Equation: y = 0.993x + 1.2Correlation Coefficient: 0.997Sample Range: 27-531 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ExpectedValues</td><td rowspan=1 colspan=1>&lt;150 mg/dL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MatrixComparison</td><td rowspan=1 colspan=1>x = serum, y = lithium heparin plasmaACE:Regression Equation: y = 1.005x - 7.9Correlation Coefficient: 0.9977Sample Range: 39-887ACE Alera:Regression Equation: y = 1.007x - 7.4Correlation Coefficient: 0.9973Sample Range: 38-884</td><td rowspan=1 colspan=1>Serum only</td></tr><tr><td rowspan=1 colspan=1>DetectionWavelength</td><td rowspan=1 colspan=1>505/692 nm</td><td rowspan=1 colspan=1>Same</td></tr></table>

# K. Standard/ Guidance Document Referenced (if applicable):

EP9-A2 Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline- Second Edition (2002).

L. Test Principle:

# ACE Cholesterol Reagent

The ACE Cholesterol Reagent is composed of a single reagent bottle.

The reagent contains:

Page 12 of 28   

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Quantity</td></tr><tr><td rowspan=1 colspan=1>ACE Cholesterol Reagent</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>4-Aminoantipyrine (AAP)</td><td rowspan=1 colspan=1>0.5mmol/L</td></tr><tr><td rowspan=1 colspan=1>p-Hydroxybenzoic acid</td><td rowspan=1 colspan=1>25 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Cholesterol oxidase (Nocardia)</td><td rowspan=1 colspan=1>&gt;150 U/L</td></tr><tr><td rowspan=1 colspan=1>Cholesterol esterase (Porcine pancreas andPseudomonas)</td><td rowspan=1 colspan=1>&gt;240 U/L</td></tr><tr><td rowspan=1 colspan=1>Peroxidase (Horseradish)</td><td rowspan=1 colspan=1>&gt;1600 U/L</td></tr><tr><td rowspan=1 colspan=1>Stabilizers, Preservatives,and Fillers</td><td rowspan=1 colspan=1></td></tr></table>

Cholesterol esters in serum are completely hydrolyzed by cholesterol esterase to free cholesterol and free fatty acids. The cholesterol liberated by the esterase, plus any endogenous free cholesterol, are both oxidized by cholesterol oxidase to yield hydrogen peroxide $\left( \mathrm { H } _ { 2 } \mathrm { O } _ { 2 } \right)$ . The hydrogen peroxide then acts to oxidatively couple p-hydroxybenzoic acid and 4-aminoantipyrine (AAP) in a reaction catalyzed by peroxidase, producing a red colored quinoneimine complex which absorbs strongly at $5 0 5 \mathrm { n m }$ .

![](images/e4f5d76b34acf4eaab66d67922743e0bae0bfab6f6dabe25111d07d521b7dd5a.jpg)

The amount of chromogen formed, determined by measuring the increase in absorbance, bichromatically at $5 0 5 \mathrm { n m } / 6 4 7 \mathrm { n m }$ , is directly proportional to the cholesterol concentration in the sample.

# ACE HDL-C Reagent

The ACE HDL-C Reagent is composed of two reagent bottles (Buffer and Color Reagent). The Buffer (R1) contains:

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Quantity</td></tr><tr><td rowspan=1 colspan=1>ACE HDL-C Buffer (R1)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Good&#x27;s Buffer</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Cholesteroloxidase (E. coli)</td><td rowspan=1 colspan=1>&lt;1000 U/L</td></tr><tr><td rowspan=1 colspan=1>Peroxidase(Horseradish)</td><td rowspan=1 colspan=1>&lt;1300 U/L</td></tr></table>

Page 13 of 28   

<table><tr><td rowspan=1 colspan=1>N,N-bis(4-sulphobutyl)-m-toluidine-disodium salt(DSBmT)</td><td rowspan=1 colspan=1>&lt;l mM</td></tr><tr><td rowspan=1 colspan=1>Accelerator</td><td rowspan=1 colspan=1>&lt;1 mM</td></tr><tr><td rowspan=1 colspan=1>Preservative</td><td rowspan=1 colspan=1>&lt;0.06%</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Oxidase(Curcubita sp.)</td><td rowspan=1 colspan=1>&lt;3000 U/L</td></tr></table>

The Color Reagent (R2) contains:

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Quantity</td></tr><tr><td rowspan=1 colspan=1>ACE HDL-C Color Reagent (R2)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Cholesterol esterase(Pseudomonas sp.)</td><td rowspan=1 colspan=1>&lt;1500U/L</td></tr><tr><td rowspan=1 colspan=1>4-Aminoantipyrine (4-AAP)</td><td rowspan=1 colspan=1>&lt;l mM</td></tr><tr><td rowspan=1 colspan=1>Detergent</td><td rowspan=1 colspan=1>&lt;2%</td></tr><tr><td rowspan=1 colspan=1>Preservative</td><td rowspan=1 colspan=1></td></tr></table>

The HDL-C Assay utilizes two reagents, the second containing a unique detergent. This detergent solubilizes only the HDL lipoprotein particles, thus releasing HDL cholesterol to react with the cholesterol esterase and cholesterol oxidase, in the presence of a chromogen to produce color. The detergent also inhibits the reaction of the cholesterol enzymes with LDL, VLDL and chylomicron lipoproteins by adsorbing to their surfaces. The amount of chromogen formed, determined by measuring the increase in absorbance bichromatically at $5 9 2 / 6 9 2 \ \mathrm { n m }$ , is directly proportional to the HDL cholesterol concentration in the sample.

HDL, LDL, VLDL, Non-Reactive LDL, VLDL, chylomicrons $^ +$ DSBmT chylomicrons

![](images/db7b688092f58d7e953598c93cb6a182440419f83c3ba56a6ad5d5fb6277758c.jpg)

# ACE LDL-C Reagent

The ACE LDL-C Reagent is composed of two reagent bottles (Buffer and Color Reagent).

The Buffer (R1) contains:

Page 14 of 28

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Quantity</td></tr><tr><td rowspan=1 colspan=1>ACE LDL-C Buffer (R1)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>MES Buffer (pH 6.3)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Detergent 1</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>Cholesterol esterase(Cellulomonas sp.)</td><td rowspan=1 colspan=1>&lt;1500 U/L</td></tr><tr><td rowspan=1 colspan=1>Cholesterol oxidase(Pseudomonas sp.)</td><td rowspan=1 colspan=1>&lt;1500 U/L</td></tr><tr><td rowspan=1 colspan=1>Peroxidase (Horseradish)</td><td rowspan=1 colspan=1>&lt;1300 ppg U/L</td></tr><tr><td rowspan=1 colspan=1>4-Aminoantipyrine (4-AAP)</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid oxidase(Curcubita sp.)</td><td rowspan=1 colspan=1>&lt;3000 U/L</td></tr><tr><td rowspan=1 colspan=1>Preservative</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr></table>

The Color Reagent (R2) contains:

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Quantity</td></tr><tr><td rowspan=1 colspan=1>ACE LDL-C Color Reagent (R2)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>MES Buffer (pH 6.3)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Detergent 2</td><td rowspan=1 colspan=1>&lt;1.0%</td></tr><tr><td rowspan=1 colspan=1>N,N-bis(4-sulphobutyl)-m-toluidine-disodium salt(DSBmT)</td><td rowspan=1 colspan=1>&lt;1.0mmol/L</td></tr><tr><td rowspan=1 colspan=1>Preservative</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr></table>

Detergent 1 solubilizes non-LDL lipoprotein particles (HDL, VLDL and chylomicrons) and releases cholesterol. The cholesterol is consumed by cholesterol esterase and cholesterol oxidase in a non-color forming reaction. In a second reaction, detergent 2 solublizes the remaining LDL particles and forms peroxide, via the enzymes cholesterol esterase and cholesterol oxidase. The peroxide, in the presence of peroxidase and two peroxidase substrates, 4-aminoantipyrine and DSBmT, results in a purple-red color.

The first reaction:

![](images/c08341d3a4240e2a4483ec647a19b7ed1b823e917497294cf3f0a522a8eb592a.jpg)

The second reaction:

![](images/e0b8d1e94351d99685b192da2ac01d6083b7003c4019bd3c5ab4f6764c5f6324.jpg)

The amount of color formed, determined by measuring the increase in absorbance bichromatically at $5 4 4 / 6 9 2 \ \mathrm { n m }$ , is directly proportional to the LDL cholesterol concentration in the sample.

# ACE Triglycerides Reagent

The ACE Triglycerides Reagent is composed of a single reagent bottle.

The reagent contains:

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Quantity</td></tr><tr><td rowspan=1 colspan=1>ACE Triglycerides Reagent</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>4-Aminoantipyrine (AAP)</td><td rowspan=1 colspan=1>0.4 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Adenosine 5&#x27;-triphosphate (ATP)</td><td rowspan=1 colspan=1>2.6 mmol/L</td></tr><tr><td rowspan=1 colspan=1>p-Chlorophenol</td><td rowspan=1 colspan=1>3.0 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Glycerol phosphate oxidase (GPO)(Microorganism)</td><td rowspan=1 colspan=1>&gt;2400 U/L</td></tr><tr><td rowspan=1 colspan=1>Lipase (Pseudomonas)</td><td rowspan=1 colspan=1>&gt;1000 U/L</td></tr><tr><td rowspan=1 colspan=1>Peroxidase (Horseradish)</td><td rowspan=1 colspan=1>&gt;540 U/L</td></tr><tr><td rowspan=1 colspan=1>Glycerol kinase (Cellulomonas)</td><td rowspan=1 colspan=1>&gt;400 U/L</td></tr><tr><td rowspan=1 colspan=1>Buffer, Stabilizers and Preservatives</td><td rowspan=1 colspan=1></td></tr></table>

Triglycerides in serum are hydrolyzed by lipase to form glycerol and free fatty acids. In the presence of adenosine triphosphate (ATP) and glycerol kinase (GK), the glycerol is converted to glycerol-1-phosphate (G-1-P) and the ATP to adenosine diphosphate (ADP). Glycerol-1-phosphate is oxidized by glycerol phosphate oxidase (GPO) to yield hydrogen peroxide $\left( \mathrm { H } _ { 2 } \mathrm { O } _ { 2 } \right)$ . The hydrogen peroxide then acts to oxidatively couple p-chlorophenol and 4-aminoantipyrine (AAP) in a reaction catalyzed by peroxidase, producing a red colored quinoneimine complex which absorbs strongly at $5 0 5 \mathrm { n m }$ .

![](images/371e0a8cec12865b7bf044a0bd78eac6b5938db9a5b1f48d235a8c67ed671751.jpg)

The amount of chromogen formed, determined by measuring the increase in absorbance bichromatically at $5 0 5 \ : \mathrm { n m } / 6 9 2 \ : \mathrm { n m }$ , is directly proportional to the triglycerides concentration in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

Precision studies were performed on one lot of the ACE Cholesterol, HDL, LDL, and Triglyceride Reagents using three serum and three lithium heparin plasma samples on one ACE and one ACE Alera Clinical Chemistry Systems. The low level samples were from a normal human patient, the high levels samples were spiked with analyte, and the mid-level samples were prepared by mixing the high and low level samples. The samples were run two times per run, with two runs being performed per day, with each run consisting of each sample being run on the ACE and the ACE Alera Clinical Chemistry Systems (total n for each sample is 20). This was done for three days (HDL) or five days (Cholesterol, LDL, Triglycerides). The results are presented below.

Cholesterol on the ACE Analyzer   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>145.6</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Plasma 1</td><td rowspan=1 colspan=1>126.0</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>246.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>Plasma 2</td><td rowspan=1 colspan=1>332.0</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>512.2</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Plasma 3</td><td rowspan=1 colspan=1>539.2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>1.3</td></tr></table>

Cholesterol on the ACE Alera Analyzer   

<table><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Mean(mg/dL)</td><td colspan="2" rowspan="1">Within Run</td><td colspan="2" rowspan="1">Total Imprecision</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV %</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV %</td></tr><tr><td colspan="1" rowspan="1">Serum 1</td><td colspan="1" rowspan="1">144.5</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">Plasma 1</td><td colspan="1" rowspan="1">124.6</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">1.6</td></tr><tr><td colspan="1" rowspan="1">Serum 2</td><td colspan="1" rowspan="1">244.4</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">0.9</td></tr><tr><td colspan="1" rowspan="1">Plasma 2</td><td colspan="1" rowspan="1">326.4</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">1.2</td></tr><tr><td colspan="1" rowspan="1">Serum 3</td><td colspan="1" rowspan="1">503.8</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">5.5</td><td colspan="1" rowspan="1">1.1</td></tr><tr><td colspan="1" rowspan="1">Plasma 3</td><td colspan="1" rowspan="1">531.8</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">7.7</td><td colspan="1" rowspan="1">1.4</td></tr></table>

HDL-C on the ACE Analyzer   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>51.3</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>Plasma 1</td><td rowspan=1 colspan=1>44.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>83.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Plasma 2</td><td rowspan=1 colspan=1>76.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>115.4</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Plasma 3</td><td rowspan=1 colspan=1>110.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.0</td></tr></table>

HDL-C on the ACE Alera Analyzer   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>49.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Plasma 1</td><td rowspan=1 colspan=1>42.5</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>77.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Plasma 2</td><td rowspan=1 colspan=1>71.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>107.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Plasma 3</td><td rowspan=1 colspan=1>102.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.9</td></tr></table>

LDL-C on the ACE Analyzer   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>89.4</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Plasma 1</td><td rowspan=1 colspan=1>75.4</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>154.6</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Plasma 2</td><td rowspan=1 colspan=1>212.4</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>339.8</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Plasma 3</td><td rowspan=1 colspan=1>360.4</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>1.9</td></tr></table>

LDL-C on the ACE Alera Analyzer   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>89.2</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Plasma 1</td><td rowspan=1 colspan=1>76.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>156.1</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Plasma 2</td><td rowspan=1 colspan=1>214.2</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>341.4</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Plasma 3</td><td rowspan=1 colspan=1>365.9</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>2.1</td></tr></table>

Triglyceride on the ACE Analyzer   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>58.0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>Plasma 1</td><td rowspan=1 colspan=1>51.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>329.5</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Plasma 2</td><td rowspan=1 colspan=1>324.3</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>601.8</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Plasma 3</td><td rowspan=1 colspan=1>596.7</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>1.2</td></tr></table>

Triglyceride on the ACE Alera Analyzer   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Serum 1</td><td rowspan=1 colspan=1>58.1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Plasma 1</td><td rowspan=1 colspan=1>51.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>Serum 2</td><td rowspan=1 colspan=1>327.9</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Plasma 2</td><td rowspan=1 colspan=1>324.6</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Serum 3</td><td rowspan=1 colspan=1>599.8</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>Plasma 3</td><td rowspan=1 colspan=1>588.4</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>13.5</td><td rowspan=1 colspan=1>2.3</td></tr></table>

Precision studies were also conducted in three physician office laboratory (POL) sites on three serum samples at three concentrations over five days. The results are as follows:

Cholesterol on the ACE Analyzer   

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>111.4</td><td rowspan=1 colspan=1>110.5</td><td rowspan=1 colspan=1>109.5</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.3 (1.2%)</td><td rowspan=1 colspan=1>0.8 (0.7%)</td><td rowspan=1 colspan=1>1.2 (1.1%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>1.4 (1.3%)</td><td rowspan=1 colspan=1>0.9 (0.8%)</td><td rowspan=1 colspan=1>1.4 (1.3%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>239.6</td><td rowspan=1 colspan=1>230.3</td><td rowspan=1 colspan=1>236.7</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>2.5 (1.0%)</td><td rowspan=1 colspan=1>1.8 (0.8%)</td><td rowspan=1 colspan=1>2.1 (0.9%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>3.0 (1.2%)</td><td rowspan=1 colspan=1>3.0 (1.3%)</td><td rowspan=1 colspan=1>2.7 (1.1%)</td></tr><tr><td rowspan=1 colspan=4>Sample 3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>364.4</td><td rowspan=1 colspan=1>347.3</td><td rowspan=1 colspan=1>356.5</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>2.5 (0.7%)</td><td rowspan=1 colspan=1>3.9 (1.1%)</td><td rowspan=1 colspan=1>2.4 (0.7%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>4.2 (1.2%)</td><td rowspan=1 colspan=1>4.1 (1.2%)</td><td rowspan=1 colspan=1>3.1 (0.9%)</td></tr></table>

# Cholesterol on the ACE Alera Analyzer

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>110.5</td><td rowspan=1 colspan=1>111.3</td><td rowspan=1 colspan=1>111.0</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>2.4 (2.2%)</td><td rowspan=1 colspan=1>2.4 (2.2%)</td><td rowspan=1 colspan=1>1.9 (1.7%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>2.6 (2.4%)</td><td rowspan=1 colspan=1>2.6 (2.4%)</td><td rowspan=1 colspan=1>2.1 (1.9%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>238.5</td><td rowspan=1 colspan=1>239.0</td><td rowspan=1 colspan=1>237.7</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>4.2 (1.8%)</td><td rowspan=1 colspan=1>3.4 (1.4%)</td><td rowspan=1 colspan=1>2.5 (1.1%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>4.9 (2.1%)</td><td rowspan=1 colspan=1>4.4 (1.8%)</td><td rowspan=1 colspan=1>2.5 (1.1%)</td></tr><tr><td rowspan=1 colspan=4>Sample 3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>356.3</td><td rowspan=1 colspan=1>359.9</td><td rowspan=1 colspan=1>358.7</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>2.2 (0.6%)</td><td rowspan=1 colspan=1>6.6 (1.8%)</td><td rowspan=1 colspan=1>2.0 (0.5%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>4.2 (1.2%)</td><td rowspan=1 colspan=1>7.1 (2.0%)</td><td rowspan=1 colspan=1>2.9 (0.8%)</td></tr></table>

HDL on the ACE Analyzer   

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>35.7</td><td rowspan=1 colspan=1>33.4</td><td rowspan=1 colspan=1>35.6</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>0.9 (2.4%)</td><td rowspan=1 colspan=1>0.6 (1.8%)</td><td rowspan=1 colspan=1>0.7 (2.0%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>1.1 (3.2%)</td><td rowspan=1 colspan=1>1.5 (4.4%)</td><td rowspan=1 colspan=1>2.1 (6.0%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>58.6</td><td rowspan=1 colspan=1>54.4</td><td rowspan=1 colspan=1>58.5</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>0.9 (1.6%)</td><td rowspan=1 colspan=1>0.5 (1.0%)</td><td rowspan=1 colspan=1>1.1 (1.9%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>1.2 (2.1%)</td><td rowspan=1 colspan=1>2.0 (3.7%)</td><td rowspan=1 colspan=1>2.9 (5.0%)</td></tr><tr><td rowspan=1 colspan=3>Sample 3</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>81.2</td><td rowspan=1 colspan=1>77.3</td><td rowspan=1 colspan=1>82.0</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.4 (1.8%)</td><td rowspan=1 colspan=1>1.0 (1.3%)</td><td rowspan=1 colspan=1>1.1 (1.3%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>1.8 (2.3%)</td><td rowspan=1 colspan=1>2.9 (3.8%)</td><td rowspan=1 colspan=1>4.1 (5.0%)</td></tr></table>

# HDL on the ACE Alera Analyzer

Page 21 of 28   

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>33.2</td><td rowspan=1 colspan=1>38.3</td><td rowspan=1 colspan=1>35.4</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.1 (3.2%)</td><td rowspan=1 colspan=1>0.9 (2.3%)</td><td rowspan=1 colspan=1>0.6 (1.8%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>1.2 (3.7%)</td><td rowspan=1 colspan=1>1.0 (2.7%)</td><td rowspan=1 colspan=1>1.8 (5.0%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>55.0</td><td rowspan=1 colspan=1>61.2</td><td rowspan=1 colspan=1>58.0</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.5 (2.7%)</td><td rowspan=1 colspan=1>1.2 (1.9%)</td><td rowspan=1 colspan=1>1.1 (1.9%)</td></tr><tr><td rowspan=1 colspan=1>Total SD(% CV)</td><td rowspan=1 colspan=1>1.9 (3.5%)</td><td rowspan=1 colspan=1>1.5 (2.5%)</td><td rowspan=1 colspan=1>2.1 (3.7%)</td></tr><tr><td rowspan=1 colspan=4>Sample 3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>76.0</td><td rowspan=1 colspan=1>86.5</td><td rowspan=1 colspan=1>81.2</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.1 (1.4%)</td><td rowspan=1 colspan=1>1.6 (1.8%)</td><td rowspan=1 colspan=1>1.5 (1.8%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>2.2 (2.8%)</td><td rowspan=1 colspan=1>2.2 (2.6%)</td><td rowspan=1 colspan=1>3.2 (4.0%)</td></tr></table>

# LDL on the ACE Analyzer

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>67.5</td><td rowspan=1 colspan=1>67.0</td><td rowspan=1 colspan=1>67.0</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>2.0 (3.0%)</td><td rowspan=1 colspan=1>0.6 (0.9%)</td><td rowspan=1 colspan=1>2.5 (3.8%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>2.1 (3.1%)</td><td rowspan=1 colspan=1>2.3 (3.5%)</td><td rowspan=1 colspan=1>2.7 (4.0%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>152.7</td><td rowspan=1 colspan=1>138.4</td><td rowspan=1 colspan=1>150.8</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>4.1 (2.7%)</td><td rowspan=1 colspan=1>4.0 (2.9%)</td><td rowspan=1 colspan=1>3.0 (2.0%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>5.3 (3.5%)</td><td rowspan=1 colspan=1>4.2 (3.0%)</td><td rowspan=1 colspan=1>4.2 (2.8%)</td></tr><tr><td rowspan=1 colspan=3>Sample 3</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>237.1</td><td rowspan=1 colspan=1>217.8</td><td rowspan=1 colspan=1>240.2</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>3.8 (1.6%)</td><td rowspan=1 colspan=1>3.3 (1.5%)</td><td rowspan=1 colspan=1>4.6 (1.9%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>5.2 (2.2%)</td><td rowspan=1 colspan=1>6.0 (2.8%)</td><td rowspan=1 colspan=1>6.6 (2.7%)</td></tr></table>

LDL on the ACE Alera Analyzer   

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>70.7</td><td rowspan=1 colspan=1>68.4</td><td rowspan=1 colspan=1>67.2</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>3.3 (4.7%)</td><td rowspan=1 colspan=1>3.0 (4.4%)</td><td rowspan=1 colspan=1>1.1 (1.6%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>3.6 (5.0%)</td><td rowspan=1 colspan=1>3.2 (4.7%)</td><td rowspan=1 colspan=1>1.8 (2.6%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>154.8</td><td rowspan=1 colspan=1>153.6</td><td rowspan=1 colspan=1>150.8</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>2.1 (1.4%)</td><td rowspan=1 colspan=1>3.6 (21.4%)</td><td rowspan=1 colspan=1>3.4 (2.3%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>4.5 (2.9%)</td><td rowspan=1 colspan=1>4.9 (3.2%)</td><td rowspan=1 colspan=1>3.5 (2.3%)</td></tr><tr><td rowspan=1 colspan=4>Sample 3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>244.6</td><td rowspan=1 colspan=1>244.9</td><td rowspan=1 colspan=1>241.9</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>3.6 (1.5%)</td><td rowspan=1 colspan=1>6.5 (2.7%)</td><td rowspan=1 colspan=1>4.3 (1.8%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>6.5 (2.7%)</td><td rowspan=1 colspan=1>7.1 (2.9%)</td><td rowspan=1 colspan=1>5.3 (2.2%)</td></tr></table>

Triglyceride on the ACE Analyzer   

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>68.8</td><td rowspan=1 colspan=1>69.3</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.0 (1.5%)</td><td rowspan=1 colspan=1>1.5 (2.1%)</td><td rowspan=1 colspan=1>1.5 (2.1%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>2.0 (3.0%)</td><td rowspan=1 colspan=1>1.9 (2.8%)</td><td rowspan=1 colspan=1>1.5 (2.1%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>267.8</td><td rowspan=1 colspan=1>271.9</td><td rowspan=1 colspan=1>262.8</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.9 (0.7%)</td><td rowspan=1 colspan=1>3.2 (1.2%)</td><td rowspan=1 colspan=1>2.1 (0.8%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>2.0 (0.7%)</td><td rowspan=1 colspan=1>3.7 (1.3%)</td><td rowspan=1 colspan=1>2.9 (1.1%)</td></tr><tr><td rowspan=1 colspan=4>Sample 3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>450.4</td><td rowspan=1 colspan=1>461.9</td><td rowspan=1 colspan=1>439.5</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>9.7 (2.1%)</td><td rowspan=1 colspan=1>8.8 (1.9%)</td><td rowspan=1 colspan=1>3.8 (0.9%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>11.2 (2.5%)</td><td rowspan=1 colspan=1>9.7 (2.1%)</td><td rowspan=1 colspan=1>5.1 (1.2%)</td></tr></table>

# Triglyceride on the ACE Alera Analyzer

<table><tr><td rowspan=1 colspan=4>Sample 1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>65.3</td><td rowspan=1 colspan=1>69.5</td><td rowspan=1 colspan=1>68.8</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>1.9 (2.9%)</td><td rowspan=1 colspan=1>1.4 (2.1%)</td><td rowspan=1 colspan=1>1.1 (1.7%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>2.1 3.2%)</td><td rowspan=1 colspan=1>1.5 (2.2%)</td><td rowspan=1 colspan=1>1.8 (2.6%)</td></tr><tr><td rowspan=1 colspan=4>Sample 2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>249.4</td><td rowspan=1 colspan=1>265.9</td><td rowspan=1 colspan=1>260.1</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>4.8 (1.9%)</td><td rowspan=1 colspan=1>2.2 (0.8%)</td><td rowspan=1 colspan=1>1.1 (0.4%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>5.9 (2.4%)</td><td rowspan=1 colspan=1>2.3 (0.9%)</td><td rowspan=1 colspan=1>1.5 (0.6%)</td></tr><tr><td rowspan=1 colspan=4>Sample 3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>POL 3</td></tr><tr><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>410.5</td><td rowspan=1 colspan=1>442.9</td><td rowspan=1 colspan=1>432.1</td></tr><tr><td rowspan=1 colspan=1>Within-Run SD(% CV)</td><td rowspan=1 colspan=1>6.8 (1.7%)</td><td rowspan=1 colspan=1>3.7 (0.8%)</td><td rowspan=1 colspan=1>3.5 (0.8%)</td></tr><tr><td rowspan=1 colspan=1>Total SD (%CV)</td><td rowspan=1 colspan=1>7.5 (1.8%)</td><td rowspan=1 colspan=1>3.7 (0.8%)</td><td rowspan=1 colspan=1>3.7 (0.9%)</td></tr></table>

b. Linearity/assay reportable range:

The linearity remains the same as in predicate devices. The measuring ranges previously established are:

Cholesterol: 6 to $6 0 0 \mathrm { m g / d L }$ HDL: $4 { \cdot } 1 2 5 \ \mathrm { m g / d L }$ LDL: $ { 3 - 8 0 0 }  { \mathrm { m g / d L } }$ Triglycerides $6 { \cdot } 1 0 0 0 \ \mathrm { m g / d L }$

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable, the traceability and stability remains the same as in predicate devices.

d. Detection limit: Not applicable, the detection limit remains the same as in predicate devices.

e. Analytical specificity: Not applicable, the specificity remains the same as in predicate devices.

f. Assay cut-off: Not applicable.

# a. Method comparison with predicate device:

A method comparison study was performed using serum samples at Physician Office Laboratories. Operators assayed serum samples on the ACE and the ACE Alera Clinical Chemistry Systems. The following linear regression data was obtained by comparing samples run in house to the POL sites using Deming analysis:

# ACE Analyzer

<table><tr><td rowspan=1 colspan=8>Cholesterol</td></tr><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95%CI ofSlope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>95% CIofIntercept</td><td rowspan=1 colspan=1>r^2 }$</td></tr><tr><td rowspan=1 colspan=1>In-houseVs. POL 1</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>41 to431</td><td rowspan=1 colspan=1>1.017</td><td rowspan=1 colspan=1>1.001to1.034</td><td rowspan=1 colspan=1>-4.5</td><td rowspan=1 colspan=1>8.2 to -0.9</td><td rowspan=1 colspan=1>0.9986</td></tr><tr><td rowspan=1 colspan=1>In-housevs. POL 2</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>42 to425</td><td rowspan=1 colspan=1>0.983</td><td rowspan=1 colspan=1>0.967to1.000</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>-2.4 to5.1</td><td rowspan=1 colspan=1>0.9985</td></tr><tr><td rowspan=1 colspan=1>In-houseVs. POL 3</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>40 to425</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.982to1.009</td><td rowspan=1 colspan=1>-0.9</td><td rowspan=1 colspan=1>-3.9 to2.0</td><td rowspan=1 colspan=1>0.9990</td></tr><tr><td rowspan=1 colspan=8>HDL</td></tr><tr><td rowspan=1 colspan=1>In-houseVs. POL 1</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>14 to102</td><td rowspan=1 colspan=1>0.955</td><td rowspan=1 colspan=1>0.927to0.983</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>-1.4 to1.7</td><td rowspan=1 colspan=1>0.9954</td></tr><tr><td rowspan=1 colspan=1>In-housevs. POL 2</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>15 to103</td><td rowspan=1 colspan=1>0.958</td><td rowspan=1 colspan=1>0.932to0.984</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>-0.6 to2.3</td><td rowspan=1 colspan=1>0.9960</td></tr><tr><td rowspan=1 colspan=1>In-houseVS. POL 3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>14 to103</td><td rowspan=1 colspan=1>1.002</td><td rowspan=1 colspan=1>0.964to1.041</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>-1.7 to2.6</td><td rowspan=1 colspan=1>0.9921</td></tr><tr><td rowspan=1 colspan=8>LDL</td></tr><tr><td rowspan=1 colspan=1>In-houseVs. POL 1</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>21 to329</td><td rowspan=1 colspan=1>0.979</td><td rowspan=1 colspan=1>0.949to1.009</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>-4.2 to4.1</td><td rowspan=1 colspan=1>0.9949</td></tr><tr><td rowspan=1 colspan=1>In-houseVs. POL 2</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>23 to329</td><td rowspan=1 colspan=1>0.955</td><td rowspan=1 colspan=1>0.924to</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>-2.5 to5.9</td><td rowspan=1 colspan=1>0.9945</td></tr></table>

Page 25 of 28   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.986</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>In-houseVs. POL 3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>25 to331</td><td rowspan=1 colspan=1>0.984</td><td rowspan=1 colspan=1>0.962to1.006</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>-2.8 to3.2</td><td rowspan=1 colspan=1>0.9973</td></tr><tr><td rowspan=1 colspan=8>Triglyceride</td></tr><tr><td rowspan=1 colspan=1>In-housevS. POL 1</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>31 to794</td><td rowspan=1 colspan=1>1.046</td><td rowspan=1 colspan=1>1.033to1.060</td><td rowspan=1 colspan=1>-4.1</td><td rowspan=1 colspan=1>-7.8 to -0.4</td><td rowspan=1 colspan=1>0.9991</td></tr><tr><td rowspan=1 colspan=1>In-housevs. POL 2</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>28 to789</td><td rowspan=1 colspan=1>1.023</td><td rowspan=1 colspan=1>1.002to1.045</td><td rowspan=1 colspan=1>-3.8</td><td rowspan=1 colspan=1>-9.7 to2.1</td><td rowspan=1 colspan=1>0.9976</td></tr><tr><td rowspan=1 colspan=1>In-houseVs. POL 3</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>29 to762</td><td rowspan=1 colspan=1>1.006</td><td rowspan=1 colspan=1>0.997to1.016</td><td rowspan=1 colspan=1>-0.5</td><td rowspan=1 colspan=1>-3.0 to2.1</td><td rowspan=1 colspan=1>0.9995</td></tr></table>

# ACE Alera Analyzer

<table><tr><td colspan="8" rowspan="1">Cholesterol</td></tr><tr><td colspan="1" rowspan="1">Site</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Range</td><td colspan="1" rowspan="1">Slope</td><td colspan="1" rowspan="1">95%CI ofSlope</td><td colspan="1" rowspan="1">Intercept</td><td colspan="1" rowspan="1">95% CIofIntercept</td><td colspan="1" rowspan="1">$r^2}$</td></tr><tr><td colspan="1" rowspan="1">In-houseVs. POL 1</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">43 to429</td><td colspan="1" rowspan="1">1.001</td><td colspan="1" rowspan="1">0.961to1.042</td><td colspan="1" rowspan="1">-5.1</td><td colspan="1" rowspan="1">-14.5 to4.2</td><td colspan="1" rowspan="1">0.9911</td></tr><tr><td colspan="1" rowspan="1">In-housevs. POL 2</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">43 to428</td><td colspan="1" rowspan="1">1.002</td><td colspan="1" rowspan="1">0.971to1.032</td><td colspan="1" rowspan="1">-6.1</td><td colspan="1" rowspan="1">-13.2 to1.0</td><td colspan="1" rowspan="1">0.9948</td></tr><tr><td colspan="1" rowspan="1">In-houseVS. POL 3</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">43 to426</td><td colspan="1" rowspan="1">0.996</td><td colspan="1" rowspan="1">0.973to1.019</td><td colspan="1" rowspan="1">-2.7</td><td colspan="1" rowspan="1">-8.0 to2.6</td><td colspan="1" rowspan="1">0.9971</td></tr><tr><td colspan="2" rowspan="1">HDL</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">In-houseVS. POL 1</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">12 to101</td><td colspan="1" rowspan="1">0.968</td><td colspan="1" rowspan="1">0.918to1.017</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">-2.3 to3.2</td><td colspan="1" rowspan="1">0.9863</td></tr><tr><td colspan="1" rowspan="1">In-housevs. POL 2</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">16 to102</td><td colspan="1" rowspan="1">0.959</td><td colspan="1" rowspan="1">0.910to1.008</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">-1.1 to4.3</td><td colspan="1" rowspan="1">0.9862</td></tr><tr><td colspan="1" rowspan="1">In-houseVs. POL 3</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">14 to103</td><td colspan="1" rowspan="1">0.953</td><td colspan="1" rowspan="1">0.916to0.989</td><td colspan="1" rowspan="1">0.3</td><td colspan="1" rowspan="1">-1.7 to2.4</td><td colspan="1" rowspan="1">0.9924</td></tr><tr><td colspan="8" rowspan="1">LDL</td></tr><tr><td colspan="1" rowspan="1">In-houseVs. POL 1</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">24 to333</td><td colspan="1" rowspan="1">0.982</td><td colspan="1" rowspan="1">0.929to1.035</td><td colspan="1" rowspan="1">2.5</td><td colspan="1" rowspan="1">-4.9 to9.8</td><td colspan="1" rowspan="1">0.9840</td></tr><tr><td colspan="1" rowspan="1">In-housevs. POL 2</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">23 to325</td><td colspan="1" rowspan="1">0.983</td><td colspan="1" rowspan="1">0.920to1.045</td><td colspan="1" rowspan="1">-0.2</td><td colspan="1" rowspan="1">-8.8 to8.4</td><td colspan="1" rowspan="1">0.9782</td></tr><tr><td colspan="1" rowspan="1">In-houseVs. POL 3</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">20 to322</td><td colspan="1" rowspan="1">1.011</td><td colspan="1" rowspan="1">0.984to1.038</td><td colspan="1" rowspan="1">-4.7</td><td colspan="1" rowspan="1">-8.3 to -1.0</td><td colspan="1" rowspan="1">0.9962</td></tr><tr><td colspan="8" rowspan="1">Triglyceride</td></tr><tr><td colspan="1" rowspan="1">In-housevs. POL 1</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">24 to333</td><td colspan="1" rowspan="1">0.977</td><td colspan="1" rowspan="1">0.956to0.999</td><td colspan="1" rowspan="1">-1.0</td><td colspan="1" rowspan="1">-6.9 to4.9</td><td colspan="1" rowspan="1">0.9975</td></tr><tr><td colspan="1" rowspan="1">In-housevs. POL 2</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">31 to755</td><td colspan="1" rowspan="1">0.997</td><td colspan="1" rowspan="1">0.970to1.023</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">-6.9 to8.0</td><td colspan="1" rowspan="1">0.9962</td></tr><tr><td colspan="1" rowspan="1">In-houseVs. POL 3</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">29 to750</td><td colspan="1" rowspan="1">0.977</td><td colspan="1" rowspan="1">0.957to0.997</td><td colspan="1" rowspan="1">-1.0</td><td colspan="1" rowspan="1">-6.6 to4.7</td><td colspan="1" rowspan="1">0.9977</td></tr></table>

b. Matrix comparison:

Matrix comparison was done by using Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline - Second Edition (2002), CLSI EP9-A2 as a guideline. Paired samples were drawn from the same patients in serum and lithium heparin plasma tubes drawn at hospital sites. Some of the samples were spiked with a solution containing a high level of analyte obtained from commercial sources.

Page 27 of 28   

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Sample#</td><td rowspan=1 colspan=1># Diluted/ #Spiked</td><td rowspan=1 colspan=1>SerumRange</td><td rowspan=1 colspan=1>Results ACE</td><td rowspan=1 colspan=1>Results ACE Alera</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>ACE:102Alera:103</td><td rowspan=1 colspan=1>0/5 ACE0/6 Alera</td><td rowspan=1 colspan=1>ACE: 40 to568 mg/dLAlera: 42 to577 mg/dL</td><td rowspan=1 colspan=1>Slope: 0.985(0.965,1.005)Intercept: -1.7 (-5.7 to2.3Correlation: 0.9947</td><td rowspan=1 colspan=1>Slope: 0.994 (0.971,1.016)Intercept: -2.5 (-7.0, 2.1)Correlation: 0.9934</td></tr><tr><td rowspan=1 colspan=1>HDL</td><td rowspan=1 colspan=1>ACE:101Alera:100</td><td rowspan=1 colspan=1>0/0</td><td rowspan=1 colspan=1>ACE: 6 to120 mg/dLAlera: 7 to123 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.015 (0.984,1.045Intercept: -0.6 (-2.1, 0.8)Correlation: 0.9884</td><td rowspan=1 colspan=1>Slope: 0.989 (0.957,1.02)Intercept: 0.4 (-1.2, 1.9)Correlation: 0.9874</td></tr><tr><td rowspan=1 colspan=1>LDL</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>0/4</td><td rowspan=1 colspan=1>ACE: 9 to460 mg/dLAlera: 9 to464 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.008 (0.989,1.028)Intercept: -2.6 (-5.0, -0.2Correlation: 0.9954</td><td rowspan=1 colspan=1>Slope: 0.995 (0.976,1.014)Intercept: -1.3 (-3.7, 1.0)Correlation: 0.9954</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>0/5</td><td rowspan=1 colspan=1>ACE: 39 to887 mg/dLAlera: 38 to884 mg/dL</td><td rowspan=1 colspan=1>Slope: 1.005 (0.991,1.019)Intercept: -7.9 (-11.1, -4.7)Correlation: 0.9977</td><td rowspan=1 colspan=1>Slope: 1.007 (0.992,1.021)Intercept: -7.4 (-10.8, -4.0)Correlation: 0.9973</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range Specific ranges for each analyte/methodology are listed in the package insert.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.